tris(2-maleimidoethyl)amine has been researched along with Thrombocytopenia* in 1 studies
1 other study(ies) available for tris(2-maleimidoethyl)amine and Thrombocytopenia
| Article | Year |
|---|---|
Novel chemical-structure TPOR agonist, TMEA, promotes megakaryocytes differentiation and thrombopoiesis via mTOR and ERK signalings.
Non-peptide thrombopoietin receptor (TPOR) agonists are promising therapies for the mitigation and treatment of thrombocytopenia. However, only few agents are available as safe and effective for stimulating platelet production for thrombocytopenic patients in the clinic.. This study aimed to develop a novel small molecule TPOR agonist and investigate its underlying regulation of function in megakaryocytes (MKs) differentiation and thrombopoiesis.. TMEA could serve as a novel TPOR agonist to promote MKs differentiation and thrombopoiesis via mTOR and ERK signaling and could potentially be created as a promising new drug to treat thrombocytopenia. Topics: Animals; Cell Differentiation; MAP Kinase Signaling System; Megakaryocytes; Mice; Mice, Inbred C57BL; Phosphatidylinositol 3-Kinases; Receptors, Thrombopoietin; Signal Transduction; Thrombocytopenia; Thrombopoiesis; TOR Serine-Threonine Kinases; Zebrafish | 2023 |